Pfizer Inc.’s EV / EBITDA at a glance
Pfizer Inc. reports ev / ebitda of 11.9x for Dec 2024. The prior period recorded 24.1x (Dec 2023). Year over year the metric moved −12.19 (−50.5%). The rolling three-period average stands at 14.6x. Data last refreshed Dec 7, 2025, 2:46 AM.
Latest reading
11.9x · Dec 2024
YoY movement
−12.19 (−50.5%)
Rolling average
14.6x
Current EV / EBITDA
11.9x
−12.19
−50.5%
Rolling average
14.6x
Latest Value
11.9x
Dec 2024
YoY Change
−12.19
Absolute
YoY Change %
−50.5%
Rate of change
3-Period Avg
14.6x
Smoothed
Narrative signal
Pfizer Inc.’s ev / ebitda stands at 11.9x for Dec 2024. Year-over-year, the metric shifted by −12.19, translating into a −50.5% rate of change versus the prior period.
Pair this momentum with product cadence, pricing power, and capital allocation moves to understand durability.
Blend with balance sheet, cash flow, and peer benchmarks from AlphaPilot’s broader dashboards to shape an investable thesis.
How ev / ebitda shapes Pfizer Inc.'s story
As of Dec 2024, Pfizer Inc. reports ev / ebitda of 11.9x. Use EV/EBITDA to benchmark acquisition multiples, leverage-adjusted valuation, and comparable transaction ranges.
Why EV/EBITDA matters
It normalizes valuation across different leverage levels, making it a go-to metric for M&A and cross-company comparisons.
Watch for cyclical swings
EBITDA can swing with cycle-sensitive businesses. Track multi-year averages and peak vs. trough to understand value ranges.
Valuation Multiples
Compare how the market prices revenue, equity, and operating cash flow versus peers and history.
Profitability & Margins
Understand cost structure and capital efficiency trends across gross, operating, and net results.
Gross Margin
65.8%
Operating Margin
25.9%
Net Profit Margin
12.6%
Return on Equity
9.1%
Return on Assets
3.8%
Growth Momentum
Track whether top-line, earnings, and free cash flow growth are accelerating or cooling.
Balance Sheet Strength
Evaluate leverage, liquidity, and cash generation capacity that underpin resilience.
Shareholder Returns
Follow dividend sustainability and cash generation relative to market value.
Pfizer Inc. (PFE) FAQs
Answers tailored to Pfizer Inc.’s ev / ebitda profile using the latest Financial Modeling Prep data.
What is Pfizer Inc.'s current ev / ebitda?
As of Dec 2024, Pfizer Inc. reports ev / ebitda of 11.9x. This reading reflects the latest filings and price data for PFE.
How is Pfizer Inc.'s ev / ebitda trending year over year?
Year-over-year, the figure shifts by −12.19 (−50.5%). Pair this context with revenue growth and free cash flow signals to gauge momentum for PFE.
Why does ev / ebitda matter for Pfizer Inc.?
The enterprise value to EBITDA ratio evaluates valuation relative to operating cash flow before capital structure impacts. For Pfizer Inc., operating within Healthcare — Drug Manufacturers - General, tracking this metric helps benchmark management's execution against close competitors.
Is Pfizer Inc.'s ev / ebitda above its recent average?
Pfizer Inc.'s rolling three-period average sits at 14.6x. Comparing the latest reading of 11.9x to that baseline highlights whether momentum is building or fading for PFE.
How frequently is Pfizer Inc.'s ev / ebitda refreshed?
Data for PFE was last refreshed on Dec 7, 2025, 2:46 AM and updates automatically every 24 hours, keeping your valuation inputs current.